Clinical trials: Myocardial Ischaemia
Coronary Artery Disease
Direct Comparison of 2D Cardiac PET With 3D Cardiac PET
Lowering the per-infusion dose of Rb-82 offers advantages of lessening radiation exposure and extending useable generator life. Prior studies have not shown equivalence of 3D vs 2D Rb-82 PET.
- Trial name
- NCT01993303
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Cardiovascular Imaging Technologies
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Percutaneous Coronary Intervention, Coronary Heart Disease
Clinical Study of Endovascular Interventional Surgical Instrument Control System and Related Consumables in Percutaneous Coronary Intervention
The goal of this study is to evaluate the safety and effectiveness of endovascular interventional surgery instrument control system （ALLVAS®robot）and supporting consumables for coronary artery interventional surgery.
- Conditions
- Percutaneous Coronary Intervention, Coronary Heart Disease, Robotic Surgical Procedures
- Trial name
- NCT05642286
- Testing
- ALLVAS® robotic-assisted PCI
- Volunteers
- 218 people
- Sponsor
- Shanghai Operation Robot Co., Ltd.
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment
research topic:helios After registration of clinical research bidders:kinhely bio-tech Co.Ltd study design:A prospective single treatment group multicenter clinical study Number of patients:Included in the subjects of 800 cases…
- Trial name
- Pro-HOPE (NCT01880879)
- Testing
- helios stent
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Kinhely Bio-tech Co., Ltd.
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Right Ventricular Infarction
The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients
This study is designed to better understand the effects of nitric oxide, a gas for inhalation, on patients with right ventricular infarction.
- Trial name
- NCT00782652
- Testing
- inhaled nitric oxide, nitrogen gas
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 3 people
- Sponsor
- Mallinckrodt
Coronary Artery Disease
A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis (GAMMA V)
The objectives of this study are: 1. To show a reduction in the late thrombosis (LT) rate following percutaneous revascularization using current interventional techniques with new stent placement and intravascular radiation…
- Trial name
- NCT00232778
- Testing
- GAMMA-Iridium-192 catheter
- Volunteers
- 579 people
- Sponsor
- Cordis US Corp.
Cardiovascular Diseases, Coronary Artery Disease
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant…
- Trial name
- LIGHT (NCT00993915)
- Testing
- Atorvastatin
- Volunteers
- 687 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)
This study will evaluate the efficacy of anacetrapib (100 mg) for 24 weeks relative to placebo, on plasma concentrations of Low Density Lipoprotein Cholesterol and assess the safety and tolerability of anacetrapib (100 mg) in…
- Trial name
- DEFINE (NCT00685776)
- Testing
- anacetrapib
- Volunteers
- 1,623 people
- Sponsor
- Merck Sharp & Dohme LLC
Stable Angina
Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina
The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4 is effective in improving exercise capacity measured by exercise treadmill testing, angina functional class, patient symptoms, quality…
- Trial name
- AGENT-4 (NCT00185263)
- Volunteers
- 116 people
- Sponsor
- Cardium Therapeutics
Coronary Artery Disease
VEST Venous Graft External Support Pivotal Study
Prospective, multi-center, randomized, within-subject-controlled , trial, enrolling patients with multi vessel atherosclerotic coronary artery disease, scheduled to undergo SVG CABG with arterial grafting of IMA to LAD and two or…
- Trial name
- VEST Pivotal (NCT03209609)
- Testing
- VEST, Coronary artery bypass vein grafts
- Where
- 17 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- Vascular Graft Solutions Ltd.
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Coronary (Artery); Disease
Trial of MiStent Compared to Xience in Japan
To compare the MT005 (MiStent) with the XIENCE with respect to target lesion failure (TLF) at 12 months in a non-inferiority trial in a "real world" patient population and to confirm that the domestic extrapolation of the…
- Trial name
- DESSOLVEJ (NCT02972671)
- Testing
- MiStent (MT005) Coronary Artery Stent, Xience Coronary Artery Stent
- Where
- 10 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Micell Technologies
Multi Vessel Coronary Artery Disease
Angiogram Based Fractional Flow Reserve in Patients With Multi-Vessel Disease
This is a prospective, observational, single-center, single-arm, clinical trial designed to assess the efficacy of FFRangio in measuring FFR obtained from angiography compared to Invasive FFR for diagnosing hemodynamically…
- Trial name
- NCT03455244
- Testing
- FFRangio
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CathWorks Ltd.
Unstable Angina
Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris
This parallel, double blind, randomized, controlled, multi-center study will evaluate the efficacy and safety of salvianolate injection in elderly patients with unstable angina pectoris.
- Trial name
- NCT03037047
- Testing
- 0.9% Sodium Chloride Injection, salvianolate injection
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Green Valley Group of China
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease, Coronary Artery Stenosis
ReZolve2 Clinical Investigation
The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.
- Trial name
- RESTORE II (NCT01845311)
- Testing
- ReZolve2 Scaffold
- Where
- 3 sites in Australia, Brazil and 1 more
- Volunteers
- 89 people
- Sponsor
- REVA Medical, Inc.
Coronary Heart Disease, Dyslipidemias
A Study of Atorvo+™ in Healthy Adult Participants
A Phase 1 study will assess the safety, tolerability, and pharmacokinetics of Atorvo+™ in healthy adult participants. .
- Trial name
- NCT06615284
- Testing
- Atorvo+™ (Arm1), Atorvo+™ +CBD (Arm 2), Atorvo+™ +CBD (Arm 3)
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Indication Bioscience LLC
Coronary Artery Disease, Coronary Atherosclerosis
Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems
The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for…
- Trial name
- ELITE (NCT00715884)
- Testing
- CYPHER® ELITE™ Sirolimus-Eluting Stent System, CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
- Where
- United States
- Volunteers
- 678 people
- Sponsor
- Cordis US Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.